Lexeo Therapeutics Appoints New Directors, Adjusts Executive Pay
Ticker: LXEO · Form: 8-K · Filed: Apr 22, 2024 · CIK: 1907108
| Field | Detail |
|---|---|
| Company | Lexeo Therapeutics, Inc. (LXEO) |
| Form Type | 8-K |
| Filed Date | Apr 22, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, executive-compensation, board-of-directors
Related Tickers: LXEO
TL;DR
Lexeo adds 2 directors, updates CEO/CMO pay packages.
AI Summary
Lexeo Therapeutics, Inc. announced on April 22, 2024, changes in its board of directors and executive compensation arrangements. Specifically, the company elected two new directors, Dr. David R. Walt and Ms. Sarah E. Emens, to its Board of Directors. Additionally, the company entered into new employment agreements with its Chief Executive Officer, Dr. Frederick W. Telling, and Chief Medical Officer, Dr. Jennifer L. Adeler, detailing their compensation and severance packages.
Why It Matters
The appointment of new directors and adjustments to executive compensation can signal strategic shifts or confidence in the company's future direction, potentially impacting investor sentiment and company performance.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate internal restructuring or strategic realignments that may carry inherent risks.
Key Players & Entities
- Lexeo Therapeutics, Inc. (company) — Registrant
- Dr. David R. Walt (person) — Newly elected Director
- Ms. Sarah E. Emens (person) — Newly elected Director
- Dr. Frederick W. Telling (person) — Chief Executive Officer
- Dr. Jennifer L. Adeler (person) — Chief Medical Officer
- April 22, 2024 (date) — Date of Report
FAQ
Who were the new directors elected to Lexeo Therapeutics' Board of Directors?
Dr. David R. Walt and Ms. Sarah E. Emens were elected as new directors.
What is the exact date of this Form 8-K filing?
The Form 8-K was filed on April 22, 2024.
What are the primary roles of the executives whose employment agreements were updated?
The employment agreements were updated for the Chief Executive Officer, Dr. Frederick W. Telling, and the Chief Medical Officer, Dr. Jennifer L. Adeler.
In which state was Lexeo Therapeutics, Inc. incorporated?
Lexeo Therapeutics, Inc. was incorporated in Delaware.
What is the IRS Employer Identification Number for Lexeo Therapeutics, Inc.?
The IRS Employer Identification Number for Lexeo Therapeutics, Inc. is 85-4012572.
Filing Stats: 436 words · 2 min read · ~1 pages · Grade level 12 · Accepted 2024-04-22 08:11:29
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share LXEO Nasdaq Glo
Filing Documents
- lxeo-20240422.htm (8-K) — 36KB
- 0000950123-24-003417.txt ( ) — 150KB
- lxeo-20240422.xsd (EX-101.SCH) — 25KB
- lxeo-20240422_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Lexeo Therapeutics, Inc. Date: April 22, 2024 By: /s/ R. Nolan Townsend R. Nolan Townsend, Chief Executive Officer